RxDoctor Payments Data

Tenzin Dekyi

Adult Health · East Elmhurst, NYNPI 1295482875

Payments from drug & device makers

$1,080in general payments, 2019–2025

Across 21 payments — averaging $51.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eisai Inc.$208
  • Merck$205
  • Johnson & Johnson$152
  • E.r. Squibb & Sons, L.L.C.$125
  • AstraZeneca$120
  • Seagen Inc.$100
  • plus $169 from 5 others

What the payments were for

  • Food & beverage$79073%
  • Education$29027%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,080 in reported general payments places this provider in the 70th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$4,214
Medicare patients
44
Services billed
76

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abiraterone Acetate150$644,467
InlytaAxitinib20$419,338
TagrissoOsimertinib Mesylate15$319,603
OrgovyxRelugolix55$220,112
XtandiEnzalutamide14$197,669
EliquisApixaban36$32,948
CreonLipase/Protease/Amylase14$21,245
ZarxioFilgrastim-Sndz11$15,700
LokelmaSodium Zirconium Cyclosilicate13$3,874
Lidocaine11$1,139
Megestrol Acetate12$916
Prednisone170$693
Prochlorperazine Maleate40$502
Ondansetron Hcl50$482
Lidocaine Hcl ViscousLidocaine Hcl22$366

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerInlyta, Eliquis$25$452,28656 claims
AstraZenecaTagrisso, Lokelma$120$323,47828 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,828 adult health providers in New York.

Other adult health in East Elmhurst

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →